Business Context and Reporting Period
This Form 8-K was filed by Zentalis Pharmaceuticals, Inc. on February 9, 2021. The report details a corporate governance event involving the expansion of the Board of Directors and the appointment of a new director.
Key Financial Metrics
The filing does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on personnel changes and associated compensation arrangements.
Material Changes
- Board Expansion: The Board of Directors increased its size from five to six members.
- New Appointment: Enoch Kariuki, Pharm.D., was appointed as a Class I director.
- Committee Roles: Dr. Kariuki was appointed to the Audit Committee and named Chairperson of the Audit Committee.
Compensation and Governance Details
Dr. Kariuki is eligible for the Non-Employee Director Compensation Program with the following terms:
- Cash Retainer: $40,000 annually for Board service plus $20,000 annually for serving as Audit Committee Chairperson.
- Equity Grant: An initial award of options to purchase 42,000 shares of common stock.
- Option Terms: Exercise price of $39.47 per share (fair market value on grant date).
- Vesting Schedule: 36 substantially equal monthly installments, contingent on continued service.
Investor Verification Checklist
- Verify the current share price relative to the $39.47 exercise price of the new director options.
- Confirm the total number of outstanding options and the impact of the 42,000 new shares on potential dilution.
- Review the Company's most recent 10-K or 10-Q for actual financial performance metrics not included in this 8-K.
- Check for any subsequent filings regarding the resignation or further appointments of other board members.